Methylene Blue 15mg capsules
// Methylene Blue: From Textile Dye to Clinical Wonder
by Sara Hover, RPh, FAARM, PCCA Director of Clinical Services
The history of methylene blue dates back to the late 19th century, when it was first synthesized by German chemist Heinrich Caro in 1876. Initially developed as a textile dye, it quickly gained popularity in the textile industry for its vibrant blue color. However, its journey from a dye to a versatile chemical agent was just the beginning.
In the 1890s, researchers began exploring potential medical applications of methylene blue. Paul Ehrlich, a German physician and Nobel laureate, investigated its antimicrobial properties and found methylene blue was effective against certain bacterial and protozoal infections. These early findings laid the foundation for its future use in pharmaceutical therapies.1
DIAGNOSTIC, ANTIMICROBIAL & ANTIVIRAL PROPERTIES
Methylene blue’s staining properties quickly caught the attention of the medical community. Surgeons realized its potential as a valuable tool in surgical procedures, particularly in enhancing visualization and precision. It subsequently was used in techniques such as lymph node mapping, where it helped identify cancerous cells in lymph nodes.2
Additionally, methylene blue exhibits potent antimicrobial properties, making it an effective option for various infections. One of the most significant breakthroughs in the pharmaceutical application came with its use in patients suffering from malaria.1 In the early 20th century, researchers discovered that methylene blue, when combined with specific antimalarial drugs, exhibited potent anti-parasitic effects. It was found to be effective against the Plasmodium genus — the parasites responsible for malaria. Methylene blue reduced the severity of malaria symptoms and accelerated recovery, saving countless lives in malaria-endemic regions.3
Methylene blue has also shown efficacy against urinary tract infections caused by certain bacteria. It acts by inhibiting bacterial growth and reducing the recurrence of infections.4
Given its broad-spectrum antiviral activity, methylene blue may be used in patients with viral infections. It is important to note that further research is needed to establish efficacy in specific viral diseases, but it has shown promise in combating respiratory viral infections such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). In experimental studies, researchers learned methylene blue demonstrated inhibitory effects on viral replication and reduced severity of respiratory viral symptoms.5
METHEMOGLOBINEMIA MANAGEMENT
Methylene blue’s role in patients with methemoglobinemia, a rare blood disorder that is characterized by reduced oxygen- carrying capacity in red blood cells, is another significant milestone. By converting methemoglobin, a dysfunctional form of hemoglobin, back to functional hemoglobin, methylene blue was proven to help restore normal oxygenation and save lives in critical situations.1
ANTIOXIDANT, ANTI-INFLAMMATORY & ANTI-APOPTOTIC PROPERTIES
In recent years, methylene blue has garnered attention for its potential in neuroprotection and mitochondrial support. Research has shown that it possesses antioxidant, anti-inflammatory and anti-apoptotic properties, making it a promising candidate for various neurological disorders.
Methylene blue’s ability to enhance mitochondrial function and stimulate mitochondrial biogenesis opened up new avenues for addressing age-related cognitive decline and neurodegenerative diseases. Researchers have explored its potential in Alzheimer’s disease, Parkinson’s disease, depression and other mental health conditions.6
ALZHEIMER’S DISEASE
Various neurotransmitter systems (cholinergic, serotonergic and glutamatergic) are believed to play important roles in the pathogenesis of Alzheimer’s disease and other cognitive disorders. These neurotransmitter systems are influenced by methylene blue. Recently, researchers suggested that methylene blue may offer a beneficial effect on the cognitive performance of patients with Alzheimer’s disease, possibly by inhibiting Tau protein aggregation. This mechanism, however, remains under debate.7
ANTIDEPRESSANT ADJUNCT
Methylene blue was also recognized as a potential antidepressant and anxiolytic agent in animal models, possibly by increasing both serotonin and dopamine levels in the hippocampus through various mechanisms.8 Studies show methylene blue exhibits inhibition of the monoamine oxidases, MAO-A and MAO-B. Due to the potential increase in serotonin, patients currently taking SSRIs, SNRIs or MAO inhibitors should use caution due to the increased potential of serotonin syndrome when combined with methylene blue.9
NEUROPROTECTIVE AGENT
Emerging research indicates that methylene blue may have neuroprotective properties, offering potential benefits for various neurological conditions. Neuroprotection refers to strategies or interventions aimed at preserving the structure and function of neurons, preventing or slowing down neuron degeneration. Methylene blue was found to possess several mechanisms that contribute to neuroprotection.10
Oxidative stress plays a crucial role in neurodegenerative disease. Methylene blue acts as an antioxidant, helping to neutralize harmful free radicals and reduce oxidative damage in the brain. This antioxidant property contributes to protecting neurons from degeneration. Another aspect of neuronal degeneration involves chronic inflammation, which is associated with the progression of neurological disorders. Methylene blue was shown to possess anti-inflammatory properties, inhibiting the release of pro-inflammatory molecules and reducing neuroinflammation. By modulating the inflammatory response, methylene blue helps protect the neurons from damage. It is important to recognize the role that apoptosis, or programmed cell death, plays in neurodegenerative conditions. Methylene blue has been found to inhibit apoptotic pathways, preventing the death of neurons and preserving their integrity.
MITOCHONDRIAL SUPPORT
Mitochondria are essential cellular organelles responsible for generating energy in the form of adenosine triphosphate (ATP). Dysfunction of mitochondria is a common feature
in neurodegenerative diseases. Methylene blue has shown remarkable effects on mitochondrial function,11 in particular as an electron carrier in the electron transport chain, facilitating the flow of electrons and enhancing ATP production. This property helps optimize mitochondrial function and improve cellular energy metabolism.
Methylene blue has also been found to promote the growth and replication of mitochondria — a process known as mitochondrial biogenesis. By increasing the number of healthy mitochondria, methylene blue enhances energy production and cellular resilience.11
Mitochondrial dysfunction can lead to the overproduction of reactive oxygen species (ROS), causing oxidative damage.
Methylene blue helps reduce ROS production and prevents oxidative stress, preserving mitochondrial integrity.
The neuroprotective and mitochondrial support properties of methylene blue potentially have broad implications for patients with neurological disorders. While more research is needed, promising studies have highlighted its potential in conditions such as Alzheimer’s disease and Parkinson’s disease, as well as Huntington’s disease and ischemic stroke.
HORMESIS
In addition to its diverse clinical applications, methylene blue garnered attention for its hormetic properties. Hormesis refers to the phenomenon in which exposure to low or moderate doses of a compound elicits beneficial physiological responses, while higher doses may be detrimental. Methylene blue exemplifies this hormetic effect: at lower doses, methylene blue exhibits an enhanced effect on mitochondrial function, whereas excessive doses are associated with toxic effects including increases in oxidative stress.1
PRECAUTIONS AND CONSIDERATIONS: PREGNANCY, BREASTFEEDING AND G6PD DEFICIENCY
While methylene blue has demonstrated a wide range of clinical applications and potential benefits, there are certain precautions and considerations that should be taken into account for specific patient populations. For example, there is limited safety data on the use of methylene blue during pregnancy and breastfeeding, and therefore it is not recommended. There is also a precaution for patients with a G6PD deficiency, an inherited condition that affects the red blood cells’ ability to properly function. So, caution is necessary when considering methylene blue in individuals with this deficiency. As is the case with any pharmaceutical, the practitioner must evaluate the risk versus benefit for each individual patient before prescribing a medication. Methylene blue is no exception.12
EVOLUTIONARY AGENT
From its humble origins as a textile dye, methylene blue has transformed into a versatile clinical agent with a wide range of potential applications. Over the years, it evolved from a surgical aid and diagnostic tool to helping patients with malaria and methemoglobinemia. The journey of methylene blue exemplifies the serendipitous discoveries that shape medical progress, demonstrating the immense potential hidden within seemingly ordinary substances.
Methylene blue’s versatility extends beyond its conventional uses, making it a compelling candidate for neuroprotection and mitochondrial support. Its antioxidant, anti-inflammatory and anti-apoptotic properties may contribute to the preservation of neuronal function, while its ability to enhance mitochondrial function provides a boost to cellular energy metabolism. As researchers continue to unveil the potential of methylene blue, it offers a ray of hope for patients with neurological disorders, bringing us closer to unlocking the mysteries of neurodegenerative diseases. //
References
1. Bruchey, A. K., & Gonzalez-Lima, F. (2008). Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue. Am J Pharmacol Toxicol. 3(1):72-79. Accessed April 2023 at pubmed.ncbi.
2. Staniloaie, D., Budin, C., Vasile, D., et al. (2022). Role of methylene blue in detecting the sentinel lymph node in colorectal cancer: In vivo vs. ex vivo technique. Exp Ther Med. 23(1):72. Accessed April 2023 at pubmed.ncbi.
3. Calderón M., Weitzel T., Rodriguez M.F., et al. (2017) Methylene blue for treating malaria. Cochrane Database Syst Rev. (10):CD012837.
4. Huang, Y. Y., Wintner, A., Seed, P. C., et al. (2018). Antimicrobial photodynamic therapy mediated by methylene blue and potassium iodide to treat urinary tract infection in a female rat model. Sci Rep. 8(1):7257. Accessed April 2023 at pubmed.ncbi.nlm.nih.gov/
5. Dabholkar, N., Gorantla, S., Dubey, S. K., et al. (2021). Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. Biomed Pharmacother. Accessed April 2023 at pubmed.ncbi.nlm.nih.gov/
6. Gureev, A. P., Sadovnikova, I. S., & Popov, V. N. (2022). Molecular Mechanisms of the Neuroprotective Effect of Methylene Blue. Biochemistry (Mosc). 87(9):940-956. Accessed April 2023 at pubmed.ncbi.nlm.nih. gov/36180986/
7. Oz, M., Lorke, D. E., & Petroianu, G. A. (2009). Methylene blue and Alzheimer’s disease. Biochem Pharmacol. 78(8), 927–932. Accessed April 2023 at pubmed.ncbi.nlm.nih.gov/
8. Alda, M., McKinnon, M., Blagdon, R., et al. (2018). Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study. Brit J of Psych, 210(1), 54-60. Accessed April 2023
article/methylene-blue-
9. de Beer, F., Petzer, J. P., & Petzer, A. (2020). Monoamine oxidase inhibition by selected dye compounds. Chem Bio Drug Des. 95(3), 355–367. Accessed April 2023 at pubmed.ncbi.nlm.nih.gov/
10. Xue, H., Thaivalappil, A., & Cao, K. (2021). The Potentials of Methylene Blue as an Anti-Aging Drug. Cells. 10(12):3379. Accessed April 2023 at ncbi.nlm.nih.gov/pmc/articles/
11. Gureev, A. P., Syromyatnikov, M. Y., Gorbacheva, T. M., Starkov, A. A., & Popov, V. N. (2016). Methylene blue improves sensorimotor phenotype and decreases anxiety in parallel with activating brain mitochondria biogenesis in mid-age mice. Neurosci Res. 13:19-27. Accessed April 2023 at pubmed.
12. Methylene Blue. (2023) Clinical Pharmacology powered by ClinicalKey. Philadelphia (PA): Elsevier. C2023. Accessed May 2023 at clinicalkey.com
